chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a medical assistant referring to multiple unspecified patients of unknown age and gender. Concurrent condition and medical history of the patients were not reported. On unknown dates, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB (lot # L044917, expiration date: 05-OCT-2018; Lot# K026666, expiration date: 22-OCT-2016) (dose and route unspecified). These vaccines were exposed to 31.5 degree Fahrenheit for 208 hours. No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
11-26-07 pm temp 102 deg F Pinpoint rash over entire body except for face and hands. rash warm to touch. Hands swollen. Dr at medical center Rx for antihistamine. No change in rash after taking Rx Dr prescribed Prednisone x 12 d plus another Rx pt did not remember name. Rash gone continues with some itching, swelling in hands.
she feels under the weather; Sweating through the night and this morning; Patient feels like she is having a beginnings of a cold; Feel really tired; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (she feels under the weather), HYPERHIDROSIS (Sweating through the night and this morning), NASOPHARYNGITIS (Patient feels like she is having a beginnings of a cold) and FATIGUE (Feel really tired) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (she feels under the weather), HYPERHIDROSIS (Sweating through the night and this morning), NASOPHARYNGITIS (Patient feels like she is having a beginnings of a cold) and FATIGUE (Feel really tired). At the time of the report, FEELING ABNORMAL (she feels under the weather), HYPERHIDROSIS (Sweating through the night and this morning), NASOPHARYNGITIS (Patient feels like she is having a beginnings of a cold) and FATIGUE (Feel really tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not reported.   Reporter did not allow further contact
Patient has been having pain and muscle spasms down her and back for 1month. It burns and is painful
Client states she has slight headache.  Palpitation, chest heaviness.  Vital signs, BP 159/94, HR 72, O2Sat 97%. Client states she feels better.  Client d/c home.
Patient was supposed to get Flu shot and accidently got a Covid vaccine. It was his 3rd dose. So far, the patient has not had any adverse affects
Abnormal pap smears; This spontaneous report was received from a company representative concerning to a female patient of unknown age. The patient's pertinent medical history, concurrent conditions and concomitant therapies were unknown by the reporter.    Prior to her the vaccine, she never had any issues with her pap smears.  In approximately 2011 (reported as 10 years ago), the patient was vaccinated with a dose of  hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (dose route, frequency, lot# and the expiration date)  for Human Papillomavirus (HPV) prevention.        After receiving the vaccine (unknown date), she started having abnormal pap smears, year after year. The friend had to repeat pap smears numerous times and even had to perform a colonoscopy (unknown results). She sought medical attention.  At the time of reporting, the outcome of smear cervix abnormal was unknown.   The reporter considered smear cervix abnormal to be related to HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast)(GARDASIL 9), reported as "the friend blames hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) for giving her abnormal pap smears".
First day fussy, tired, fever 101, anorexia, irritation at site. 2nd day inflammation, grew x 4 days, Sat 9/6 peak inflammation, hot, red circular.  1 week after injection large (10.5 cm x 8 cm) circular erythematous border with central clearing with firm nodule at site.  Fever x 2 days.
Fever over 100, chills, headache, dizziness, indigestion, loss of appetite, fatigue
Chills; fever; aches; weakness; This is a spontaneous report from a contactable consumer (patient herself).  A 65-year-old non-pregnant female patient received second dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection Batch/Lot number: EL8982, Expiration Date was not reported), via an unspecified route of administration, administered in right arm on 31Jan2021 (at the age of 65-year-old) as a single dose for covid-19 immunisation. Medical history included hypertension (High blood pressure), blood cholesterol increased (high cholesterol). Concomitant medications included amlodipine ; omega-3-acid ethyl ester (LOVAZA).  The patient historical vaccination included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection Batch/Lot number: EL1283, Expiration Date was not reported), via an unspecified route of administration, administered in right arm on 10Jan2021 10:00am for covid-19 immunisation. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient had not been diagnosed with COVID-19 prior to vaccination and had not tested positive since the vaccination. The patient does not have any Allergies to medications, food, or other products. On 31Jan2021 10:00 PM patient experienced Chills fever aches weakness. Tylenol treatment received for the adverse event.Therapeutic measures were taken as a result of chills, fever, aches, weakness. The outcome of the events was reported as recovered.  Follow-up (12MAY2021): Follow-up attempts completed. No further information expected.
Patient came by on 1/3/18 and stated that her arm was still tender and felt like it sometimes had a knot in it since her flu vaccine on 9/26/2017. She said it sometimes hurt to raise her arm. I asked if she had seen a doctor regarding the problem. She said she had not seen a doctor, but uses the Clinic. I recommended that she have it examined.
Patient obtained 1st pfizer vaccine on 4/24/21 and then started having symptoms of cervical transverse myelitis on 5/1/21.  A 2nd pfizer vaccine was received on 5/15/21. A 1.5T MRI of her cervical spine on 5/18/21 diagnosed cervical transverse myelitis which was confirmed with a 3T MRI cervical spine on 5/18/21. Patient hospitalized on 6/26/21 for IV solumedrol 1 gram daily x 5 days for treatment of cervical transverse myelitis. CSF and additional MRIs obtained.
9x10 cm area of redness + induration on (R) arm was given antibiotics for cellulitis.
Starting few days after shot, she started having upper then lower back pain, left > right arm pain, left > right leg pain, severe muscle spasms in left leg, numbness in left leg, weakness in both legs, blurry vision and balance problems. This progressively worsened over 2 weeks then started to improve, overall 75% better by 1 month out from the shot. At that time she presented for elevated blood pressure which was also new onset. Exam findings revealed mild ataxia on heel-to-toe walking, asymmetric lower extremity reflexes, and generalized muscle weakness of both upper and lower extremities. Otherwise neuro exam normal.
Information regarding Hib-titer Vaccine (haemophilus b conjugate vaccine(diphtheria crm 197 protein conjugate)injection) was received from a physician, the mother of a 7 year old male patient who, experienced decreased immune responsiveness after having completed a primary series of Hib-titer at 15 months of age, in 07/1997. Product Details: Indication for HIb-titer vaccine was immunization. Product series was administered in 06/1996, 08/1996,  10/1996, and completed in 07/1997. Dose regimen was 0.5ml 1 time per day (IM). Concomitant therapy: concomitant therapy included Tri-Immunol Vaccine(diphtheria and tetanus toxoids and pertussis vaccine absorbed injection, and Orimune vaccine (poliovirus live oral trivalent solution). Event Details: On 05/21/2004 a physician the mother of a 7 year old male patient reported that her son received 4 doses of Hib-titer, the first dose at 2 months of age(06/96), second dose at 4 months of age(08/96), the third dose at 6 months of age(10/96) and in 07/1997 at 15 months of age, received his fourth dose completing his primary series. The reporter indicated that because her son has suffered with "chronic sinusitis, treated with various antibiotics" since he was 9 months old and since he "tested positive for Haemophilus B", after a throat culture was performed in 12/2003, she decided to "do a titer to see if he had acquired adequate immunity from Hib-titer". On 04/01/2004, a  titer was performed, which resulted in a titer of 0.35. The reporter stated,  "an optimum level would be 1.0". Since her son had a " sub-optimal response to Hib-titer(decreased immune responsiveness), she was considering re-vaccination to get good immunity. "the reporter also stated that her son's physician, where all the child's vaccines were administered, was not aware of the sub-optimal response to the hib-titer. Test Results: Culture Throat (results "positive for Haemophilus B and Streptococcus) was done in 12/2003. Antibody test(results:"antibody titer showed titer of 0.35.") was done on 04/01/2004. No additional information was available at the time of the report.
Vaccines that were administered beyond use date after thaw process; This spontaneous case was reported by a paramedic and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccines that were administered beyond use date after thaw process) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027H21B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 28-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On 28-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccines that were administered beyond use date after thaw process). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccines that were administered beyond use date after thaw process) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient age was reported as 36 year 1 Month.  No concomitant medications were reported It was unknown if patient had acute illness at the time of vaccination and up to one month before. It was unknown if patient had been diagnosed with or tested positive for COVID-19. Patient reported no adverse reactions after the administration of vaccine. No treatment medications were reported
Large, red raised spot to the left of the injection site, warm to the touch and itchy, about 4 inches in diameter.
She had an allergic reaction, a rash all over her body and itching after the dose.; She had an allergic reaction, a rash all over her body and itching after the dose.; This is a spontaneous report from a contactable consumer . A 54-year-old female patient received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection) via an unspecified route of administration on 09Apr2021 as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. Consumer reported regarding her housekeeper who got her first dose on 09Apr2021. She had an allergic reaction a rash all over her body and itching after the dose on an unspecified date in Apr2021. Her doctor gave her allergy medication. She took it and she was ok after 1 week. The outcome of the events was recovered on an unspecified date in Apr2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
The patient experienced no symptoms.; A patient was administered an improperly stored dose of PROQUAD; This spontaneous report was received from a Medical Assistant, referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant medications, and historical drugs were not reported.     On 01-JUL-2020, the patient was vaccinated with an improperly stored dose of  measles, mumps, rubella and varicella (oka-merck) virus vaccine live  recombinant Human albumin (rHA)(PROQUAD) via subcutaneous route (strength,dose number, dose, frequency, and anatomical location, were unknown) with lot # S031704, and expiration date 06-APR-2021, reconstituted with a properly stored sterile diluent(MERCK STERILE DILUENT).     The administered dose of the vaccine experienced the temperature excursion of -13.3°C degrees Celsius for 1 hour and 15 minutes, and had a previous temperature excursion of ( -1.8°C) degrees Celsius for 4 hours and 27 minutes; and of (-13.4°C) degrees Celsius for 1 hour. There was a digital data logger involved.
Wrong diluent used: MA used sterile water instead of saline to dilute vaccine. No adverse symptoms
6/14/2005 Fever started decreased intake of food and fluids.  6/15/2005 leg swollen, no redness seen by doctor otitis media, phorymsites, pneumonia, Sent to ER for IV fluids, 6/16/2005 seen by doctor no fever for 24 hours.
The pt developed a tender, red, swollen and warm area around the site of the vaccinia vaccination; treated with Levaquin 500mg day X 5 days.
Erythema multiforme over chest, back, upper extremities equally on both thighs, hives over groin. Mom reports facial swelling the evening of the vaccination this resolved by the time of my evaluation.
Today was my second dose of the COVID vaccine and just a few short minutes after the injection the injection site start itching. At just about the 15 min wait time after ionjection a nurse asked if i was feeling ok. I told her i was feeling gine but my arm was very itchy. She checked the site and I had redness all around the site and welt size hives around the site. She asked me to stay 15 min longer and I agreed. Shortly after that the hive started to spread to my neck and chest area and I became lightheaded and faint feeling. I became very hot. They gave me and injection of benadryl and since my BP was high and my syptoms were not going away completly I was taken to the ER for monitoring and IV fluids. There I was given more Benadryl, steroids, Pepcid and IV fluids and monitored. I felt much better and was released to go home with a RX for 4 days of steroids.
Patient did not feel well after his vaccine and spent the day following his vaccine in bed.  Around 7pm the day after, he felt well enough to get up an play cards.  At this point he discovered his left hand (specifically his thumb and index finger) were numb and he could not move those 2 fingers - immediately dropping all the cards.  Pt reported to the pharmacy at 2:45pm on 11/24 reporting the reaction.  He is still not able to move those fingers, they are numb, but no pain.  I advised pt to seek medical attention at quick care or the er.
Headache, fever, body aches started 2/2/21 and subsided 2/3/21 Arm /injection site is red, swollen, warm, itchy, painful started 2/2/21
Bivalent vaccines have undergone several temperature excursions and been administered to patient; No adverse event; Bivalent vaccines have undergone several temperature excursions and been administered to patient; This spontaneous case was reported by a nurse and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Bivalent vaccines have undergone several temperature excursions and been administered to patient), PRODUCT TEMPERATURE EXCURSION ISSUE (Bivalent vaccines have undergone several temperature excursions and been administered to patient) and NO ADVERSE EVENT (No adverse event) in a 27-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7146B) for COVID-19 prophylaxis.     Unknown whether patient ever been diagnosed with/ tested positive for COVID-19.     On 24-Sep-2022 at 3:24 PM, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .5 milliliter. On 24-Sep-2022 at 3:24 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Bivalent vaccines have undergone several temperature excursions and been administered to patient). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Bivalent vaccines have undergone several temperature excursions and been administered to patient) and NO ADVERSE EVENT (No adverse event). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Bivalent vaccines have undergone several temperature excursions and been administered to patient), PRODUCT TEMPERATURE EXCURSION ISSUE (Bivalent vaccines have undergone several temperature excursions and been administered to patient) and NO ADVERSE EVENT (No adverse event) outcome was unknown.           No concomitant medication was reported. On an unknown date, patient had received dose 1, dose 2, dose 3 of moderna vaccines. Route was Intramuscular and body site was deltoid for all three doses. Patient had received on deltoid body site for dose 4.  It was reported that refrigeration excursions identified, state vaccine was housed in these units. There were excursions noted. Manufactures were notified and the state department made aware of the situation. The Nurse called for a clinic that she was assisting. The clinic had a similar issue with vaccines stored in their freezer. Vaccines stored in the refrigerator that underwent several temperature excursions going back to Aug-2022.  Date vial moved from freezer to refrigerator was 07-Sep-2022.  No adverse reactions reported for the patient.  No treatment information was provided.
This spontaneous report was received from a pharmacist regarding a patient of unknown demographics. There was no information about concurrent condition and historical medication. On an unknown date the patient was vaccinated with improperly stored RECOMBIVAX HB INJ 10/1.0 MCRG/ML (microgram/milliliter) lot # L010595, expiration date- 12-NOV-2016. No concomitant medication was reported. No adverse event was reported. The outcome of the event was unknown. No product quality complaint (PQC) was involved. Additional information is not expected because we cannot contact physician.
A few hrs following injection, PT experienced extremely forceful heartbeat for several hrs, with no elevation in heart rate. Also reports chest pain with difficult excercise, not present before vaccination.
burning sensation over part of chest/ ribs were burning/ left leg was burning; Left arm started to tingle/tingling in  lower leg/foot/felt pins and needles; Left hand was shaking; Shooting pain; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a physician and describes the occurrence of BURNING SENSATION (burning sensation over part of chest/ ribs were burning/ left leg was burning), PARAESTHESIA (Left arm started to tingle/tingling in  lower leg/foot/felt pins and needles), TREMOR (Left hand was shaking) and PAIN (Shooting pain) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.  On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BURNING SENSATION (burning sensation over part of chest/ ribs were burning/ left leg was burning), PARAESTHESIA (Left arm started to tingle/tingling in  lower leg/foot/felt pins and needles), TREMOR (Left hand was shaking) and PAIN (Shooting pain). At the time of the report, BURNING SENSATION (burning sensation over part of chest/ ribs were burning/ left leg was burning), PARAESTHESIA (Left arm started to tingle/tingling in  lower leg/foot/felt pins and needles), TREMOR (Left hand was shaking) and PAIN (Shooting pain) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment information was provided.  Three of patients friends had the exact same symptoms.   Most recent FOLLOW-UP information incorporated above includes: On 22-Oct-2021: Follow-up received contains no new information.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 29-MAY-2015, the patient was vaccinated with an improperly stored dose of RECOMBIVAX HB 10 microgram/1 ml (lot#J010613, expiration date 11-JUN-2016). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion four times. The total cumulative excursion time (hour), the lowest recorded temperature (Fahrenheit degree/Celsius) and the type of excursion (R/F) for each time were 48, 0 and R; 48, 1 and R; 24, -1 and R; 72, unknown and R. The storage criteria was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
Information was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. Medical history, concurrent conditions, and concomitant medications were not provided. The patient's healthcare provider (unspecified healthcare professional), recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In 01-DEC-2015 (Unclear if date of vaccination was in DECEMBER 2015 or was on 01-DEC-2015), a healthcare provider (unspecified healthcare professional) at a pharmacy administered the ZOSTAVAX (lot number, dosage and route of administration not provided) to the patient. In 01-JAN-2017 (Unclear if date was in JANUARY 2017 or on 01-JAN-2017) the patient was treated by her healthcare provider at a clinic for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death; aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
He was to receive Fluzone (6 months and up) and not to have received FluBlok for 18 yrs and up
Vaccine site pink rash, urinary bleeding, swelling in extremities, blurry vision, lethargy and fever.